Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-07-28
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 78
- Registration Number
- NCT02848443
- Locations
- π«π·
La PitiΓ© SalpΓͺtriΓ¨re Centre Investigation clinique Paris Est, Paris, France
π©πͺKlinikum Wolfsburg Medizinische Klinik II, Wolfsburg, Germany
π«π·Institut Gustave Roussy DITEP, Villejuif, France
Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2016-06-21
- Last Posted Date
- 2021-10-08
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 13
- Registration Number
- NCT02808442
- Locations
- πΊπΈ
Children's Hospital Los Angeles, Los Angeles, California, United States
πΊπΈChildren's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
πΊπΈUniversity of Texas Southwestern Medical Center, Dallas, Texas, United States
Efficacy and Safety of S 47445 Versus Placebo as Adjunctive Treatment in Depressed Patients Not Fully Recovered From Depressive Symptoms With a Current Antidepressant Treatment
- Conditions
- Interventions
- First Posted Date
- 2016-06-20
- Last Posted Date
- 2020-01-03
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 400
- Registration Number
- NCT02805439
- Locations
- π§π¬
Diagnostic Consultative center "Tchaika", Varna, Bulgaria
π§π¬Mental health centre - Vratsa, Vratsa, Bulgaria
π¨πΏSoukroma psychiatricka ambulance, Brno, Czechia
Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukaemia
- First Posted Date
- 2016-04-21
- Last Posted Date
- 2021-10-01
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 25
- Registration Number
- NCT02746952
- Locations
- πΊπΈ
Massachusetts General Hospital, Boston, Massachusetts, United States
πΊπΈHospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
πΊπΈUniversity of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Study Evaluating S 95005 Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Colorectal Cancer Who Are Non-eligible for Intensive Therapy
- Conditions
- Interventions
- First Posted Date
- 2016-04-19
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 154
- Registration Number
- NCT02743221
- Locations
- π³π±
VieCurie Medisch Centrum, Interne Geneeskunde, Tegelseweg 210, Venlo, Netherlands
π΅π±Centralny Szpital Kliniczny MSW Klinika Onkologii i Hematologii, Warszawa, Poland
π΅π±Szpitale Pomorskie Sp. z o.o. Oddzial Onkologii i Radioterapii, Gdynia, Poland
A Study to Evaluate the Long-term Safety of Patients With Advanced Lymphoid Leukemia Who Have Been Previously Administered With UCART19
- Conditions
- Interventions
- First Posted Date
- 2016-04-12
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 28
- Registration Number
- NCT02735083
- Locations
- πΊπΈ
Colorado Blood Cancer Institute, Denver, Colorado, United States
π―π΅Hokkaido University Hospital, Sapporo, Japan
πΊπΈChildren's Hospital Los Angeles, Los Angeles, California, United States
Phase II of BAX2398/5-FU/Calcium Levofolinate in Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-03-03
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 84
- Registration Number
- NCT02697058
- Locations
- π―π΅
Chiba Cancer Center, Chiba-shi, Chiba-Ken, Japan
π―π΅Kyoto University Hospital, Kyoto-shi, Kyoto-Fu, Japan
π―π΅Cancer Institute Hospital of JFCR, Koto-ku, Tokyo-To, Japan
Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation
- Conditions
- Interventions
- First Posted Date
- 2015-12-17
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 153
- Registration Number
- NCT02632708
- Locations
- πΊπΈ
UCLA Medical Center, Los Angeles, California, United States
πΊπΈHackensack University Medical Center, Hackensack, New Jersey, United States
πΊπΈJohns Hopkins University, Baltimore, Maryland, United States
Efficacy and Safety of 3 Doses of S47445 Versus Placebo in Patients With Alzheimer's Disease at Mild to Moderate Stages With Depressive Symptoms
- Conditions
- Interventions
- First Posted Date
- 2015-12-10
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 500
- Registration Number
- NCT02626572
- Locations
- π²π½
Centro de Estudios Clinicos Y Especialidades Medicas Sc, Monterrey, Mexico
π΅π±Nzoz Centrum Kultury, Higieny I Zdrowia Psychicznego, Bydgoszcz, Poland
π΅π±Osrodek Alzheimerowski Sp. z o.o., Scinawa, Poland
Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation
- First Posted Date
- 2015-06-25
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 95
- Registration Number
- NCT02481154
- Locations
- πΊπΈ
UCLA Oncology Center, Los Angeles, California, United States
πΊπΈUniversity of California San Francisco, San Francisco, California, United States
πΊπΈUniversity of Miami, Miami, Florida, United States